Melanie Korsen
Overview
Explore the profile of Melanie Korsen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
98
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rauber S, Schulte-Mecklenbeck A, Willison A, Hagler R, Jonas M, Pul D, et al.
J Neuroinflammation
. 2024 Nov;
21(1):286.
PMID: 39497174
Background: Immune dysregulation is a hallmark of autoimmune diseases of the central nervous system (CNS), characterized by an excessive immune response, and primary CNS tumors (pCNS-tumors) showing a highly immunosuppressive...
2.
Pfeuffer S, Wolff S, Aslan D, Rolfes L, Korsen M, Pawlitzki M, et al.
Neurology
. 2024 Jun;
103(2):e209574.
PMID: 38870471
Background And Objectives: Relapse and MRI activity usually decline with aging but are replaced by progression independent of relapse activity (PIRA) in patients with multiple sclerosis (PwMS). However, several older...
3.
Rauber S, Forster M, Schuller J, Willison A, Golombeck K, Schroeter C, et al.
Int J Mol Sci
. 2024 Jan;
25(2).
PMID: 38255863
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) of still unclear etiology. In recent years, the search for biomarkers facilitating its diagnosis, prognosis, therapy response,...
4.
Rolfes L, Pfeuffer S, Skuljec J, He X, Su C, Oezalp S, et al.
Cells
. 2023 May;
12(9).
PMID: 37174643
Cladribine has been approved for the treatment of multiple sclerosis (MS) and its administration results in a long-lasting depletion of lymphocytes. As lymphopenia is known to hamper immune responses to...
5.
Pfeuffer S, Rolfes L, Ingwersen J, Pul R, Kleinschnitz K, Korsen M, et al.
Neurol Neuroimmunol Neuroinflamm
. 2023 Apr;
10(3).
PMID: 37041077
Background And Objectives: B cell-depleting antibodies were proven as effective strategy for the treatment of relapsing multiple sclerosis (RMS). The monoclonal antibody ocrelizumab was approved in 2017 in the United...
6.
Rauber S, Willison A, Korsen M, Kolsche T, Golombeck K, Plaack B, et al.
Front Immunol
. 2023 Jan;
13:1037214.
PMID: 36618356
Introduction: Given the varying severity of coronavirus disease 2019 (COVID-19) and the rapid spread of Severe-Acute-Respiratory-Syndrome-Corona-Virus-2 (SARS-CoV-2), vaccine-mediated protection of particularly vulnerable individuals has gained increasing attention during the course...
7.
Pape K, Rolfes L, Steffen F, Muthuraman M, Korsen M, Meuth S, et al.
Ther Adv Neurol Disord
. 2022 Dec;
15:17562864221142924.
PMID: 36568489
Background: For treatment of relapsing-remitting multiple sclerosis (RRMS), a broad range of disease-modifying therapies (DMT) is available. However, few comparative effectiveness studies between different drugs have been performed. Objectives: This...
8.
Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis
Regner-Nelke L, Pawlitzki M, Willison A, Rolfes L, Oezalp S, Nelke C, et al.
Neurol Res Pract
. 2022 Nov;
4(1):55.
PMID: 36336685
Background: Therapeutic options targeting inflammation in multiple sclerosis (MS) have evolved rapidly for relapsing-remitting MS, whereas few therapies are available for progressive forms of MS, in particular secondary progressive MS...
9.
Pawlitzki M, Nelke C, Korsen M, Meuth S, Ruck T
Eur J Neurol
. 2022 Mar;
29(4):1284-1287.
PMID: 35253967
Background And Purpose: To provide further evidence for sirolimus, a mammalian target of rapamycin inhibitor, as a treatment strategy for patients with inclusion body myositis (IBM). Methods: We acquired longitudinal...
10.
Rauber S, Korsen M, Huntemann N, Rolfes L, Muntefering T, Dobelmann V, et al.
J Neurol Neurosurg Psychiatry
. 2022 Feb;
93(9):978-985.
PMID: 35193952
Background: Vaccination has proven to be effective in preventing SARS-CoV-2 transmission and severe disease courses. However, immunocompromised patients have not been included in clinical trials and real-world clinical data point...